Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
Phillip J MeaseDafna D GladmanAtul DeodharDennis G McGonaglePeter NashWolf-Henning BoehnckeAlice GottliebXie L XuStephen XuElizabeth C HsiaChetan S KaryekarPhilip S HelliwellPublished in: RMD open (2021)
ClinicalTrials.gov: NCT02319759.URL: https://clinicaltrials.gov/ct2/show/NCT02319759; Registered 18 December 2014.
Keyphrases
- phase ii study
- placebo controlled
- double blind
- open label
- phase ii
- phase iii
- study protocol
- image quality
- computed tomography
- dual energy
- clinical trial
- juvenile idiopathic arthritis
- contrast enhanced
- high intensity
- early onset
- positron emission tomography
- protein kinase
- drug induced
- magnetic resonance
- locally advanced
- rheumatoid arthritis
- disease activity